Cladribine Tablets under FDA Review
Cladribine Tablets is an experimental treatment that has been studied in relapsing forms of multiple sclerosis. The FDA has granted a priority review which means a decision for FDA approval could occur with 6 months. EMD Serono announced that a decision on this oral therapy is expected in the last quarter of the year in 2010.
BY: Barry Singer, MD DATE: July 28, 2010 TOPIC: MS Research News